Anika Therapeutics, Inc.
HealthcareNASDAQ:ANIK · NASDAQ Global Select
+$0.00 today
Vol 0.05M · Avg 0.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-7.6%
avg -3.4%
ROIC
-6.6%
avg 3.5%
ROA
-5.7%
avg -1.9%
Analysis
ROA is currently the strongest return metric at -5.7% versus its period average of -1.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Cheryl Renee Blanchard | Executive Chair | $1.41M | — | 62 | $270,892.00 | 2.04% |
Stephen D. Griffin | President, Principal Financial Officer, CEO & Director | $818,148.00 | — | 40 | $45,973.00 | 0.35% |
David Colleran | Executive Vice President, General Counsel & Corporate Secretary | $724,581.00 | — | 54 | $6,448.00 | 0.05% |
Ian W. McLeod | Senior VP, Chief Accounting Officer & Treasurer | $489,601.00 | — | 60 | $17,663.00 | 0.13% |
Lisa Funiciello | VP & Chief Human Resources Officer | — | — | — | — | — |
Matthew Hall | Executive Director of Corporate Development & Investor Relations | — | — | — | — | — |
Ben Joseph | Vice President of Commercial & Corporate Development | — | — | — | $20,403.00 | 0.15% |
James Chase | Senior Vice President of International Sales & Marketing | — | — | — | $3,000.00 | 0.02% |
Mark Namaroff | Vice President of Investor Relations, ESG & Corporate Communications | — | — | 63 | — | — |
Mira Leiwant | Senior Vice President of Regulatory, Quality & Clinical Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$223,200.16
Sells
0
$0.00
Net Sentiment
+$223,200.16
Net buying
Most Active
HENNEMAN JOHN B III
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 1, 2026 | HENNEMAN JOHN B III Direct | Buy | 5.0K | $14.66 | $73,319.50 | |
| Apr 30, 2026 | Griffin Stephen D. Direct | Buy | 12.2K | $12.29 | $149,880.66 |
Analysis
Insiders reported 2 buys worth $223,200.16 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $223,200.16. HENNEMAN JOHN B III was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +34.8% | -8.2% (13yr)1 analysts |
| Revenue | N/A | N/A | +9.2% | +2.8% (13yr)1 analysts |
| Net Income | N/A | N/A | +37.8% | -8.7% (13yr)1 analysts |
| EBIT | N/A | N/A | +34.7% | N/A1 analysts |
Analysis
Recent growth has been strongest in Net Income at +37.8% over three years. Forward estimates point to Revenue at +2.8% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Quipt Home Medical Corp.
QIPT
$162.30M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Owlet, Inc.
NYSE:OWLT
$84.14M
Anixa Biosciences, Inc.
NASDAQ:ANIX
$84.04M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Accuray Incorporated
ARAY
$40.60M
Who manages ANIK?
Anika Therapeutics, Inc. (ANIK) lists 10 active executives. The top listed executive is David Colleran, Executive Vice President, General Counsel & Corporate Secretary.
Are ANIK insiders buying or selling?
Recent insider activity shows net buying of $16.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.